Clotrimazole topical has been assigned to pregnancy category B by the FDA. Systemic absorption is minimal following topical or vaginal administration. Animals given high doses intravaginally have not revealed evidence of teratogenicity. High oral doses resulted in embryotoxicity and maternal toxicity. In clinical trials involving women in their second and third trimester, clotrimazole treatment of vaginal candidiasis was not associated with fetal harm. Clotrimazole use has not been well studied during the first trimester. Clotrimazole should only be used during the first trimester when need has been clearly established.

See references

There are no data on the excretion of clotrimazole into human milk. However, systemic absorption is minimal after topical and vaginal administration. The manufacturer recommends that caution be used when administering clotrimazole topical to nursing women.

See references